Novartis long-acting Signifor OK'd for rare hormonal disorder

Novartis won the FDA's approval on 16 December to market a long-acting version of the company's Signifor (pasireotide), a next-generation somatostatin analogue (SSA), as a treatment for patients with acromegaly, a rare and life-threatening endocrine disorder, which is caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels.